Faden LB - Search Results

1

Monoclonal antibody successes in the clinic.

Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Reichert JM, et al. Among authors: faden lb. Nat Biotechnol. 2005 Sep;23(9):1073-8. doi: 10.1038/nbt0905-1073. Nat Biotechnol. 2005. PMID: 16151394

2

Competitiveness in follow-on drug R&D: a race or imitation?

DiMasi JA, Faden LB. DiMasi JA, et al. Among authors: faden lb. Nat Rev Drug Discov. 2011 Jan;10(1):23-7. doi: 10.1038/nrd3296. Epub 2010 Dec 10. Nat Rev Drug Discov. 2011. PMID: 21151030 Review.

3

Comparing patient access to pharmaceuticals in the UK and US.

Cohen J, Cairns C, Paquette C, Faden L. Cohen J, et al. Appl Health Econ Health Policy. 2006;5(3):177-87. doi: 10.2165/00148365-200605030-00004. Appl Health Econ Health Policy. 2006. PMID: 17132032

4

Patient access to pharmaceuticals: an international comparison.

Cohen J, Faden L, Predaris S, Young B. Cohen J, et al. Eur J Health Econ. 2007 Sep;8(3):253-66. doi: 10.1007/s10198-006-0028-z. Epub 2007 Feb 6. Eur J Health Econ. 2007. PMID: 17279403

5

Racial disparities among clinical research investigators.

Getz K, Faden L. Getz K, et al. Am J Ther. 2008 Jan-Feb;15(1):3-11. doi: 10.1097/MJT.0b013e31815fa75a. Am J Ther. 2008. PMID: 18223347

6

Off-label use reimbursement.

Cohen J, Wilson A, Faden L. Cohen J, et al. Food Drug Law J. 2009;64(2):391-403. Food Drug Law J. 2009. PMID: 19999289

7

Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?

Faden LB, Milne CP. Faden LB, et al. Food Drug Law J. 2008;63(3):683-700. Food Drug Law J. 2008. PMID: 19031668 No abstract available.

8

Are Medicare plans complying with CMS regulation?

Cohen J, Young B, Rochon S, Faden L. Cohen J, et al. Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):133-9. doi: 10.1586/14737167.8.2.133. Expert Rev Pharmacoecon Outcomes Res. 2008. PMID: 20528402

9

Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence.

Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Faden L, et al. Health Policy. 2011 May;100(2-3):134-43. doi: 10.1016/j.healthpol.2010.10.020. Epub 2010 Dec 24. Health Policy. 2011. PMID: 21185616 Review.

10

Comment: Assessment of Changes in Utilization of Health-Care Services After Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents.

Faden L, Soumerai SB. Faden L, et al. Ann Pharmacother. 2011 Feb;45(2):283. doi: 10.1345/aph.1M620c. Ann Pharmacother. 2011. PMID: 21304028 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page